Quest Diagnostics Releases 2024 Corporate Responsibility Report

25.06.25 15:07 Uhr

Werte in diesem Artikel
Aktien

154,05 EUR -0,50 EUR -0,32%

SECAUCUS, N.J., June 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report.

Quest Diagnostics supported diverse initiatives in 2024

The theme of the report, Care Starts Here, reflects the pivotal role Quest plays in an individual's healthcare, providing insights from laboratory diagnostics to drive well-informed decisions. The report details Quest's accomplishments in 2024 across the company's four strategic pillars of corporate responsibility: health access, employee and community engagement, governance and ethics, and environmental sustainability.  

"Care runs deep in the Quest culture, energizing our more than 55,000 colleagues to deliver on the Quest Purpose, working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President. "As this year's report highlights, we created several exciting new innovations and programs in 2024 to improve health quality and access, not only for our patients, but also for our employees and the communities we serve. We look forward to building on this momentum throughout 2025 and beyond."

In 2024, Quest:

  • Supported nearly 40 programs through the Quest Diagnostics Foundation with organizations committed to improving clinical and community health outcomes
  • Donated approximately $13 million in corporate giving and Foundation grants to organizations focused on disaster relief, health research and local health initiatives
  • Provided approximately one million donated or discounted test requisitions (which often include several tests)
  • Generated employee and corporate donations for over 650 nonprofits through the company's Employee Matching Gifts program
  • Extended its board of directors by welcoming a new director, Robert Carter, a former Executive Vice President and Chief Information Officer for FedEx®, whose expertise in technology and logistics supports Quest's continuous improvement initiatives focused on quality and efficiency
  • Introduced approximately 50 innovative new testing services focused on improving access across several disease areas, including Alzheimer's disease, certain cancers and HIV
  • Spent approximately $300 million on goods and services from small U.S. businesses
  • Reduced usage of electricity and single-use plastics and continued to transition the company's courier fleet in the U.S. to electric and hybrid vehicles
  • Made progress toward securing International Organization for Standardization (ISO) 14001-2015 certification for environmental management for two additional labs in our Marlborough, Massachusetts. and Lewisville, Texas facilities

To read the full report, click on 2024 Corporate Responsibility Report.

About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

questhealth.com logo (PRNewsfoto/Quest Diagnostics)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-releases-2024-corporate-responsibility-report-302490233.html

SOURCE Quest Diagnostics

In eigener Sache

Übrigens: Quest Diagnostics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Quest Diagnostics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Quest Diagnostics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Quest Diagnostics Inc.

Wer­bung

Analysen zu Quest Diagnostics Inc.

DatumRatingAnalyst
25.06.2018Quest Diagnostics OverweightBarclays Capital
20.10.2017Quest Diagnostics BuyMizuho
25.07.2017Quest Diagnostics BuyMizuho
05.06.2017Quest Diagnostics BuyMizuho
12.05.2017Quest Diagnostics HoldArgus Research Company
DatumRatingAnalyst
25.06.2018Quest Diagnostics OverweightBarclays Capital
20.10.2017Quest Diagnostics BuyMizuho
25.07.2017Quest Diagnostics BuyMizuho
05.06.2017Quest Diagnostics BuyMizuho
26.04.2017Quest Diagnostics BuyMizuho
DatumRatingAnalyst
12.05.2017Quest Diagnostics HoldArgus Research Company
07.03.2017Quest Diagnostics Equal WeightBarclays Capital
21.10.2016Quest Diagnostics NeutralMizuho
22.04.2016Quest Diagnostics Equal WeightBarclays Capital
22.04.2016Quest Diagnostics Sector PerformRBC Capital Markets
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Quest Diagnostics Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen